XML 155 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Intangible Assets and Goodwill
 12 Months Ended
Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]  
Intangible Assets and Goodwill
Intangible Assets and Goodwill
The following table summarizes the carrying amount of our intangible assets and goodwill, net of accumulated amortization: 
 
 
 
December 31, 2019
 
December 31, 2018
 
Estimated
Life (years)
 
Cost
 
Accumulated
Amortization
 
Net
 
Cost
 
Accumulated
Amortization
 
Net
Licensing Rights
3-8
 
$
57.0

 
$
(34.7
)
 
$
22.3

 
$
39.0

 
$
(29.3
)
 
$
9.7

Patents
7
 
10.5

 
(10.5
)
 
—

 
10.5

 
(10.5
)
 
—

Purchased technology
6-16
 
4,710.5

 
(1,388.7
)
 
3,321.8

 
4,710.5

 
(1,079.1
)
 
3,631.4

Other Intangibles
5
 
0.4

 
(0.2
)
 
0.2

 
0.4

 
(0.2
)
 
0.2

Total
 
 
$
4,778.4

 
$
(1,434.1
)
 
$
3,344.3

 
$
4,760.4

 
$
(1,119.1
)
 
$
3,641.3

Goodwill
Indefinite
 
$
5,040.3

 
$
(2.9
)
 
$
5,037.4

 
$
5,040.3

 
$
(2.9
)
 
$
5,037.4


During 2019 and 2018, we capitalized $18.0 and $8.0, respectively, related to regulatory approval and commercial milestones related to in-licensing arrangements.
During the third quarter 2019, the U.S. patent term extension to a composition of matter patent for STRENSIQ was granted, which resulted in an increase in the estimated useful life of the STRENSIQ intangible asset and will result in lower amortization expense in future periods.
Amortization expense was $315.0, $321.1 and $320.2 for the years ended December 31, 2019, 2018 and 2017, respectively. Assuming no changes in the gross cost basis of intangible assets, the total estimated amortization expense for finite-lived intangible assets is approximately $298.0 for each of the years ending December 31, 2020 through December 31, 2024.
As of December 31, 2019, the net book value of our purchased technology includes $2,992.4 associated with the KANUMA intangible asset, which we acquired in the acquisition of Synageva BioPharma Corp. As part of our standard quarterly procedures, we reviewed the KANUMA asset as of December 31, 2019 and determined that there were no indicators of impairment. Cash flow models used in our assessments are based on our commercial experience to date with KANUMA and require the use of significant estimates, which include, but are not limited to, long-range pricing expectations and patient-related assumptions, including patient identification, conversion and retention rates. We will continue to review the related valuation and accounting of this asset as new information becomes available to us.